3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Conditions
Ovarian Neoplasms
5
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
4
Glioblastoma
4
Carcinoma, Renal Cell
4
Sarcoma, Alveolar Soft Part
3
Sarcoma
3
Gliosarcoma
3
Fallopian Tube Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Solitary Fibrous Tumor, Pleural
2
Mesothelioma, Malignant
2
Colorectal Neoplasms
2
Carcinosarcoma
2
Carcinoma, Ovarian Epithelial
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neoplasm Metastasis
1
Interventions
Paclitaxel
34
Carboplatin
27
pembrolizumab
20
Bevacizumab
16
Letrozole
13
Megestrol Acetate
10
Cisplatin
9
lenvatinib
8
olaparib
7
dostarlimab
7
Metformin
7
durvalumab
6
abemaciclib
6
Radiotherapy
6
Everolimus
6
niraparib
5
Specimen Handling
5
Nivolumab
5
Medroxyprogesterone Acetate
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
Fluorouracil
5
Docetaxel
5
Biopsy
5
temsirolimus
4
rucaparib
4
Oxaliplatin
4
Fulvestrant
4
Doxorubicin
4
sapanisertib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Endometrial Neoplasms
×
cediranib
×
Clear all
NCT03570437
2022-03-02
COPELIA
University of Manchester
Phase 2
Unknown
124 enrolled